Aequus Pharmaceuticals Inc V.AQS

Alternate Symbol(s): AQSZF

Healthcare

Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on developing and commercializing, differentiated products in ophthalmology. Its pipeline products include PAUL Glaucoma Implant, ZIMED PF, and REV-0100 / ReVision. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease. PAUL has introduced many design features and unified these into one device and offers a solution for patients with moderate to severe glaucoma. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. REV-0100 works by reducing levels of a toxic lipid called lipid bisretinoid, which accumulates within the retina in material called lipofuscin.

TSXV:AQS - Post by User

Aequus Pharmaceuticals Inc

Bullboard Posts

Comment by Actuarialon Mar 07, 2017 10:53am

113 Views

Post# 25943648

RE:"Their goal is to be profitable this year" said Ceo Janzen

AQS is going to release their results I believe. Will see how far it is away from profitable soon. Numbers won't lie. It would require around $1M per month or $3M revenue per quarter to be break-even. Currently AQS generate around $100K sales per month.

Bullboard Posts

FE Battery Metals begins 2024 winter drill program